EE337 Cost-Effectiveness of Nirmatrelvir/Ritonavir in High-Risk Swedish Adults Including Post-Acute COVID Syndrome (PACS) From a Societal Perspective
Abstract
Authors
M. Aldvén M. Kądziela C. Gerdesköld A. Arash Rahimi F. Nilsson